Diffusion Pharmaceuticals Inc. (DFFN): Price and Financial Metrics
GET POWR RATINGS... FREE!
DFFN Stock Price Chart Interactive Chart >
DFFN Price/Volume Stats
| Current price | $6.80 | 52-week high | $42.75 |
| Prev. close | $6.97 | 52-week low | $5.10 |
| Day low | $6.56 | Volume | 29,385 |
| Day high | $6.96 | Avg. volume | 55,188 |
| 50-day MA | $7.42 | Dividend yield | N/A |
| 200-day MA | $15.00 | Market Cap | 13.87M |
Diffusion Pharmaceuticals Inc. (DFFN) Company Bio
Diffusion Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing products for ophthalmology, oncology, and dermatology. The company is based in Charlottesville, Virginia.
Latest DFFN News From Around the Web
Below are the latest news stories about Diffusion Pharmaceuticals Inc that investors may wish to consider to help them evaluate DFFN as an investment opportunity.
Is Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Expensive At $0.40? Heres How To Know.In last trading session, Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) saw 1.58 million shares changing hands with its beta currently measuring 1.47. Companys recent per share price level of $0.40 trading at $0.04 or 11.60% at ring of the bell on the day assigns it a market valuation of $39.72M. That closing price of DFFNs stock is Is Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN) Expensive At $0.40? Heres How To Know. Read More » |
Diffusion Pharmaceuticals to Present at H.C. Wainwright BioConnect, Participate in Biotech Showcase and Bio Partnering at JPM during “J.P. Morgan Week 2022”CHARLOTTESVILLE, Va., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, announced today that the Company will present at H.C. Wainwright BioConnect and participate in Biotech Showcase and BIO Partnering at JPM. All three events are scheduled alongside the J.P. Morgan 40th Annual Healthcare Conferen |
Diffusion Pharmaceuticals Doses First Patients in ILD-DLCO TrialThird of Three TSC Oxygenation TrialsCHARLOTTESVILLE, Va., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Diffusion Pharmaceuticals Inc. (NASDAQ: DFFN) (“Diffusion” or the “Company”), a biopharmaceutical company developing novel therapies that enhance the body’s ability to deliver oxygen to areas where it is needed most, today announced it has dosed the first patients in its ILD-DLCO Trial. The trial will evaluate the Company’s lead product candidate, trans sodium crocetinate (“TSC”), in patients with previo |
Glioblastoma Pipeline Analysis | Clinical Trials Report 2021 by DelveInsightLos Angeles, USA, Dec. 13, 2021 (GLOBE NEWSWIRE) -- Glioblastoma Pipeline Analysis | Clinical Trials Report 2021 | DelveInsight There are approximately 150+ key companies developing Glioblastoma therapies. The companies with Glioblastoma drug candidates in the most advanced stage are Kintara Therapeutics, Diffusion Pharmaceuticals, Celgene Corporation, Bio-Thera Solutions. DelveInsight''s " Glioblastoma Pipeline Insight " report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in the Glioblastoma pipeline landscapes. It comprises Glioblastoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Glioblastoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlig... |
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent 11,185,523Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer Claims Related to Use of TSC with Radiotherapy and Chemotherapy for Treatment of Cancer |
DFFN Price Returns
| 1-mo | N/A |
| 3-mo | -45.60% |
| 6-mo | -55.41% |
| 1-year | -82.00% |
| 3-year | -95.23% |
| 5-year | -99.61% |
| YTD | -55.41% |
| 2021 | -61.64% |
| 2020 | 72.56% |
| 2019 | -76.85% |
| 2018 | -88.76% |
| 2017 | -47.79% |
Loading social stream, please wait...